As shown in Figure 5C, mice immunized with the TMV-LMP1 peptide vaccine were significantly protected from the 38C13-LMP1 tumor challenge (p = 0.012), compared to the PBS-immunized control group, or compared to the survival of mice challenged with wild-type 38C13 cells (p = 0.042). This evidence concerns the gene PDLIM7 and neoplasm.